The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Background: People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion. They have been repeatedly shown to induce modest natriuresis and reduce HbA1c, blood pressure, weight, and albuminuria in patients with type 2 diabetes. However, the effects of these agents on kidney and cardiovascular events have not been extensively studied in patients with type 2 diabetes and established kidney disease. Methods: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial aims to compare the efficacy and safety of canagliflozin versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with diabetes and established kidney disease. CREDENCE is a randomized, double-blind, event-driven, placebo-controlled trial set in in 34 countries with a projected duration of ∼5.5 years and enrolling 4,401 adults with type 2 diabetes, estimated glomerular filtration rate ≥30 to <90 mL/min/1.73 m 2, and albuminuria (urinary albumin:creatinine ratio >300 to ≤5,000 mg/g). The study has 90% power to detect a 20% reduction in the risk of the primary outcome (α = 0.05), the composite of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death. Conclusion: CREDENCE will provide definitive evidence about the effects of canagliflozin on renal (and cardiovascular) outcomes in patients with type 2 diabetes and established kidney disease. Trial Registration: EudraCT number: 2013-004494-28; ClinicalTrials.gov identifier: NCT02065791.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An acute reduction in eGFR occurs with other classes of kidney-protective therapies, such as RAS inhibitors and SGLT2 inhibitors, and has been associated with long-term kidney protection (6,11,31,32).”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“There is substantial overlap between the FLOW population and the populations studied in the dedicated kidney outcome studies with SGLT2is (CREDENCE, DAPA-CKD and EMPA-KIDNEY) [15,30,32]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationWorldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Research works printed but not linked: 1
- 3 International Diabetes Federation: IDF Diabetes Atlas, 7th edition. Brussels, Belgium, International Diabetes Federation, 2015.
Cited by
Items 101–200 of 251
Canivell, S., Mata‐Cases, M., Vlacho, B., Gratacòs, M., Real, J., Mauricio, D., & Franch‐Nadal, J. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2018374 · Cited by 29
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
Jiménez, D. L., Cherney, D. Z. I., Bjornstad, P., Castilla‐Guerra, L., & Miramontes‐González, J. P. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2017 · Cited by 27
Novel therapeutic agents for the treatment of diabetic kidney disease
Hartman, R. E., Rao, S., Churchwell, M. D., & Lewis, S. J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1811231 · Cited by 27
Sarafidis, P. A., Ferro, C. J., Morales, E., Ortíz, A., Małyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J. M., Fouque, D. P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz137 · Cited by 27
Mohebi, R., Liu, Y., Hansen, M. K., Yavin, Y., Sattar, N. A., Pollock, C. A., Butler, J., Jardine, M., Masson, S., Heerspink, H. J. L., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01916-2 · Cited by 26
Self-citationÅkerblom, A., Oldgren, J., Latva‐Rasku, A., Johansson, L., Lisovskaja, V., Karlsson, C., Oscarsson, J., & Nuutila, P. (2019) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2018.1515281 · Cited by 25
Liao, J., Kang, A., Xia, C., Young, T. K., Tanna, G. L. D., Arnott, C. G., Pollock, C. A., Krishnan, A. V., Agarwal, R., Bakris, G. L., et al. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101331 · Cited by 25
Self-citationYi, Y., Kwon, E., Yun, G., Park, S., Jeong, J. C., Na, K. Y., Chin, H. J., Yoo, S., Kim, S., Oh, T. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52078-4 · Cited by 25
The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Loutradis, C., Papadopoulou, E., Angeloudi, E., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191029111713 · Cited by 25
Torres, E. M., Fernández, Ó., Carrascal, P., Ruíz-Beato, E., Pérez, E. E., Estrada, R. M., Gómez‐García, T., Jiménez, M., Hidalgo‐Vega, Á., & Merino, M. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-4946-8 · Cited by 25
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Canagliflozin and Renal Outcomes in Diabetic Nephropathy
Isreb, M., Al-Makki, A. A., & Buatois, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1909687 · Cited by 25
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
Oshima, M., Neal, B., Toyama, T., Ohkuma, T., Li, Q., de Zeeuw, D., Heerspink, H. J. L., Mahaffey, K. W., Fulcher, G., Canovatchel, W., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019121312 · Cited by 23
Self-citationMalik, A. H., Yandrapalli, S., Goldberg, M. D., Jain, D., Frishman, W. H., & Aronow, W. S. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000265 · Cited by 23
Metsarinne, K. P., Pietilä, M., Kantola, I. M., Stenman, L. K., Hätinen, O.-P., Vesikansa, A., Poussa, T. A., & NISKANEN, L. K. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.12.012 · Cited by 23
Loutradis, C., Papadopoulou, E., Theodorakopoulou, M. P., Karagiannis, A. I., & Sarafidis, P. A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0514 · Cited by 23
Miyoshi, H., Kameda, H., Yamashita, K., Nakamura, A., & Kurihara, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13064 · Cited by 23
McLarnon, S. R., Patel, B., Irsik, D. L., Sun, J., Ocasio, H., Crislip, G. R., Jin, C., Chen, J., Baban, B., Polichnowski, A. J., et al. (2018) · Clinical Science · doi:10.1042/cs20171630 · Cited by 22
Triantafylidis, L. K., Hawley, C. E., Fagbote, C. O., Li, J., Genovese, N., & Paik, J. M. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019876499 · Cited by 22
Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?
Tofte, N., Persson, F., & Rossing, P. R. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00759-4 · Cited by 20
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M., Baigent, C., et al. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz009 · Cited by 19
Arnott, C. G., Li, J., Cannon, C. P., de Zeeuw, D., Neuen, B. L., Heerspink, H. J. L., Charytan, D. M., Agarwal, A., Huffman, M. D., Figtree, G. A., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14386 · Cited by 19
Self-citationInagaki, N., Harashima, S., & Iijima, H. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1473378 · Cited by 18
Martínez, J. J. G. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.03.005 · Cited by 18
Woo, V. C., Connelly, K. A., Lin, P., & McFarlane, P. A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1576479 · Cited by 18
Canagliflozin and iron metabolism in the CREDENCE trial
Koshino, A., Heerspink, H. J. L., Jongs, N., Badve, S. V., Arnott, C. G., Neal, B. C., Jardine, M., Mahaffey, K. W., Pollock, C. A., Perkovic, V., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae198 · Cited by 17
Self-citationRabbani, S. A., El‐Tanani, M., Kumar, R., Saini, M., El‐Tanani, Y., Sharma, S., Aljabali, A. A. A., Hajeer, E., & Rizzo, M. (2025) · Pharmaceuticals · doi:10.3390/ph18081130 · Cited by 17
McCoy, I. E., Han, J., Montez‐Rath, M. E., Chertow, G. M., & Rhee, J. J. (2020) · Clinical Diabetes · doi:10.2337/cd19-0087 · Cited by 17
Lin, S., Chen, C., Wang, K.-L., Wu, K., & Li, S. (2022) · Nutrients · doi:10.3390/nu14102148 · Cited by 17
Kuriyama, S. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1673-0 · Cited by 17
New Glucose-Lowering Agents for Diabetic Kidney Disease
de Vos, L. C., Hettige, T., & Cooper, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.01.002 · Cited by 17
Kubica, J., Kubica, A., Grzelakowska, K., Stolarek, W., Grąbczewska, Z., Michalski, P., Niezgoda, P., Bartuś, S., Budaj, A., Dąbrowski, M., et al. (2023) · Cardiology Journal · doi:10.5603/cj.a2021.0133 · Cited by 16
Tobe, S. W., Mavrakanas, T. A., BAJAJ, H. S., Levin, A., Tangri, N., Slee, A. E., Neuen, B. L., Perkovic, V., Mahaffey, K. W., Rapattoni, W., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1450 · Cited by 16
Self-citationSGLT2 inhibitors: practical considerations and recommendations for cardiologists
Opingari, E., Partridge, A. C. R., Verma, S., & BAJAJ, H. S. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000561 · Cited by 16
Skelley, J. W., Carter, B. S., & Roberts, M. Z. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s168472 · Cited by 16
Yu, J., Zhou, Z., Mahaffey, K. W., Matthews, D. R., Neuen, B. L., Heerspink, H. J. L., Jardine, M., Li, J., Perkovic, V., Neal, B. C., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.09.050 · Cited by 16
Self-citationCardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?
Bielach-Bazyluk, A., Małyszko, J., & Zbroch, E. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1481714 · Cited by 15
Kruger, D. F., & Valentine, V. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00826-w · Cited by 15
Sacre, J. W., Magliano, D. J., & Shaw, J. E. (2020) · Diabetes Care · doi:10.2337/dc20-0654 · Cited by 15
Durkin, M. B., & Blais, J. D. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00953-4 · Cited by 15
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Charytan, D. M., Yu, J., Jardine, M., Cannon, C. P., Agarwal, R., Bakris, G. L., Greene, T., Levin, A., Pollock, C. A., Powe, N. R., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08980621 · Cited by 15
Self-citationJanuzzi, J. L., Sattar, N. A., Vaduganathan, M., Magaret, C. A., Rhyne, R. F., Liu, Y., Masson, S., Butler, J., & Hansen, M. K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02779-5 · Cited by 14
Pharmacological Management of Diabetic Nephropathy
Papademetriou, V., Alataki, S., Stavropoulos, K., Papadopoulos, C. E., Bakogiannis, K., & Tsioufis, K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164749 · Cited by 14
Li, J., Arnott, C. G., Heerspink, H. J. L., MBiostat, Q. L., Cannon, C. P., Wheeler, D. C., Charytan, D. M., Barraclough, J., Figtree, G. A., Agarwal, R., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025045 · Cited by 14
Self-citationMcHugh, K. R., DeVore, A. D., Mentz, R. J., Edmonston, D. L., Green, J. B., & Hernandez, A. F. (2018) · Clinical Cardiology · doi:10.1002/clc.23054 · Cited by 13
Kadowaki, T., Yamamoto, F., Taneda, Y., Naito, Y., Clark, D., Lund, S. S., Okamura, T., & Kaku, K. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1898585 · Cited by 13
Schernthaner, G., Groop, P., Kalra, P. A., Ronco, C., & Taal, M. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13994 · Cited by 13
Nashawi, M., Sheikh, O., Battisha, A., Ghali, A. N., & CHILTON, R. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10046-w · Cited by 13
van der Hoek, S., Jongs, N., Oshima, M., Neuen, B. L., Stevens, J., Perkovic, V., Levin, A., Mahaffey, K. W., Pollock, C. A., Greene, T., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000161 · Cited by 12
Self-citationThe Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins
Bodnar, P., Mazurkiewicz, M., Chwalba, T., Romuk, E. B., Ciszek-Chwalba, A., Jacheć, W., & Wojciechowska, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082236 · Cited by 12
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
Charytan, D. M., Mahaffey, K. W., Jardine, M., Cannon, C. P., Neal, B. C., Heerspink, H. J. L., Agarwal, R., Bakris, G. L., de Zeeuw, D., Levin, A., et al. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003270 · Cited by 12
Self-citationShivakumar, O., Sattar, N. A., & Wheeler, D. C. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz292 · Cited by 12
Self-citationA New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
Chaurasia, P., Dholariya, S. J., Kotadiya, F., & Bhavsar, M. H. (2021) · Cureus · doi:10.7759/cureus.18300 · Cited by 12
SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective
KUMAR, K. M. P., Unnikrishnan, A., Jariwala, P. V., Mehta, A., Chaturvedi, R., Panchal, S., Lakhani, P., Acharya, R., & Dixit, J. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_377_23 · Cited by 11
Sridhar, V. S., Neuen, B. L., Fletcher, R. A., Slee, A. E., Ang, F. G., Rapattoni, W., Arnott, C. G., Cherney, D. Z. I., Perkovic, V., Wheeler, D. C., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15112 · Cited by 11
Self-citationChen, A. X., Fletcher, R., Neuen, B. L., Neal, B. C., & Arnott, C. G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15751 · Cited by 12
Self-citationFerreira, J. P., Marques, P., Anker, S. D., Butler, J., Filippatos, G. S., Sharma, A., Vasques‐Nóvoa, F., Mendonça, L., Neves, J. S., Packer, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70289 · Cited by 11
Hussain, A. K. B., Abdelgadir, E., Rashid, F., Alhaj, A., Thadani, P., & Bashier, A. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.028 · Cited by 10
Kim, J. Y., Steingroever, J., Lee, K. H., Oh, J. S., Choi, M., Lee, J. M., Larkins, N., Schaefer, F. S., Hong, S. H., Jeong, G. H., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020394 · Cited by 10
Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
Silva‐Cardoso, J., Sheikh, O., Nashawi, M., Pham, S. V., Gallegos, K. M., Dinkha, L. R., & CHILTON, R. J. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.13007 · Cited by 10
Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes
Nalugo, M., Harroun, N., Li, C., Belaygorod, L., Semenkovich, C. F., & Zayed, M. A. (2020) · Vascular Medicine · doi:10.1177/1358863x20961153 · Cited by 10
Woo, V. C., Bell, A., CLEMENT, M. A., Noronha, L., Tsoukas, M. A., Camacho, F., Traina, S., Georgijev, N., Culham, M. D., Rose, J. B., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13573 · Cited by 10
Siriwardana, A. N., Buizen, L., Jun, M., Kotwal, S. S., Arnott, C. G., Jardine, M., Levin, A., Heerspink, H. J. L., Charytan, D. M., Pollock, C. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16190 · Cited by 9
Self-citationBramlage, P., Lanzinger, S., Mühldorfer, S., Milek, K., Gillessen, A., Veith, R., Ohde, T., Danne, T., Holl, R. W., & Seufert, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01840-5 · Cited by 9
Yu, J., Sweeting, A., Gianacas, C., Houston, L., Lee, V. Y., Fletcher, R. A., Perkovic, V., Li, Q., Neuen, B. L., Berwanger, O. B., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15267 · Cited by 8
Self-citationAmbery, P., Greasley, P. J., Menzies, R. I., Brynne, L., Kulkarni, S., Oscarsson, J., & Davenport, A. P. (2024) · Clinical Science · doi:10.1042/cs20240605 · Cited by 8
Muhajiriansyah, M., & Binuko, R. S. D. (2023) · Health Information Jurnal Penelitian · Cited by 8
Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?
Cheng, J. W. M., Colucci, V. J., Kalus, J. S., & Spinler, S. A. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018816466 · Cited by 8
Wahyuni, T., Lianawati, L., Harianto, J. W., & Khusnal, E. (2020) · Electronic Journal of General Medicine · doi:10.29333/ejgm/7808 · Cited by 8
Sada, K., Hidaka, S., Kashima, J., Morita, M., Sada, K., & Shibata, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13795 · Cited by 8
SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos, P. I., Divani, M., Eleftheriadis, T., Mertens, P. R., & Liakopoulos, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180524114033 · Cited by 8
Cardiovascular outcome trials of glucose-lowering therapies
Khunti, K., Davies, M. J., & Seidu, S. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1763796 · Cited by 7
Morello, C. M., Awdishu, L., Lam, S., Heman, A., & Bounthavong, M. (2024) · Kidney360 · doi:10.34067/kid.0000000597 · Cited by 7
Nashawi, M., Sheikh, O., Battisha, A., Mir, M., & CHILTON, R. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09996-y · Cited by 7
Yi, T. W., Atiquzzaman, M., Zheng, Y., Smyth, B. J., Jardine, M., & Levin, A. (2022) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221145068 · Cited by 7
Self-citationSchwarzenbach, M., Bernhard, F. E., Czerlau, C., & Sidler, D. (2021) · World Journal of Transplantation · doi:10.5500/wjt.v11.i7.254 · Cited by 7
Kang, A., Smyth, B. J., Neuen, B. L., Heerspink, H. J. L., Tanna, G. L. D., Zhang, H., Arnott, C. G., Hockham, C., Agarwal, R., Bakris, G. L., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15091 · Cited by 6
Self-citationFerreira, J. P., Marques, P., Anker, S. D., Butler, J., Filippatos, G. S., Sharma, A., Vasques‐Nóvoa, F., Mendonça, L., Neves, J. S., Packer, M., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70093 · Cited by 5
Somaili, M., Oraibi, O., Darraj, M., Hassan, A., Moafa, E., Kulaybi, A., Shubayli, S., Moafa, R. H., Mghfori, G., Jaafari, A., et al. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230706125244 · Cited by 5
Kagawa, T., Sugama, J., Nishizaki, H., Moritoh, Y., & Watanabe, M. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.10.006 · Cited by 4
Weir, M. R., Gogate, J. P., Damaraju, C. V., Correa‐Rotter, R., & Mahaffey, K. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14539 · Cited by 4
Self-citationShahady, E. J., & Leahy, J. L. (2018) · Clinical Diabetes · doi:10.2337/cd18-0064 · Cited by 4
Sharma, A., Butler, J., Zieroth, S. R., Giannetti, N., & Verma, S. (2019) · Diabetic Medicine · doi:10.1111/dme.14140 · Cited by 4
Comments on the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular disease
Jiménez-Navarro, M. F., Castro, A., Pradas, S. B., Álvarez, C. C., Gómez‐Doblas, J. J., Martín, D. M., del Prado, S., Valencia-Serrano, F. M., Lesmes, I. B., Peralta, F. G., et al. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.11.018 · Cited by 4
O’Hara, D. V., Neuen, B. L., & Jardine, M. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00809-x · Cited by 4
Self-citationMorillas, C., Escalada, J., Palomares, R., Bellido, D., Peralta, F. G., & Pérez, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0671-x · Cited by 4
Neumiller, J. J., Rhee, C. M., & Kalantar‐Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000484669 · Cited by 4
The Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Neuropathy
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2640-9411 · Cited by 3
Wu, C., Wei, M. A., Li, A., Zhu, Q., Guo, J., Sun, A., Gu, X., Li, Y., & 宫雁冰 (2026) · Biomedicines · doi:10.3390/biomedicines14071427 · Cited by 3
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4643-7 · Cited by 3
Key Updates in Cardio-Nephrology from 2018: Springboard to a Bright Future
Rangaswami, J., Soman, S. S., & McCullough, P. A. (2019) · Cardiorenal Medicine · doi:10.1159/000498916 · Cited by 3
Metabolic Disorder-Related Hypertension
Guo, Y., Zhao, J., Wang, H., Liu, S., Huang, T., & Chang, G. (2019) · Springer eBooks · doi:10.1007/978-981-15-0591-1_15 · Cited by 3
Maddaloni, E., & Buzzetti, R. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3012 · Cited by 3
Comentarios a la guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular
Grupo de Trabajo Conjunto de la SEC y la SEEN para la guía ESC 2019 sobre diabetes, P. Y. E. C. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.11.011 · Cited by 3
Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
Paramasivan, A. M., Purushothaman, A., & Desouza, C. V. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1106-1 · Cited by 2
Novel Treatments and the Future of DKD: What Is on the Horizon?
Wu, H., & Batuman, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_28 · Cited by 2
(2021) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000242 · Cited by 2
Metadata
- Authors
- Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., Levin, A., Pollock, C., Wheeler, D. C., Xie, J., Zhang, H., Zinman, B., Desai, M., Perkovic, V., & on behalf of the CREDENCE study investigators
- Affiliations
- The University of Sydney (AU)
- Stanford Medicine (US)
- Richard L. Roudebush VA Medical Center (US)
- University of Chicago (US)
- Brigham and Women's Hospital (US)
- Janssen Research & Development (United States) (US)
- University of Utah (US)
- University Medical Center Groningen (NL)
- University of British Columbia (CA)
- University College London (GB)
- Peking University First Hospital (CN)
- Mount Sinai Hospital (CA)
- UNSW Sydney (AU)
- ORCID
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 46
- Issue
- 6
- Pages
- 462-472
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- PMC
- PMC5804835
- OpenAlex
- W2772844083
- Cited by
- 234
- References
- 32
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 15 · 2023: 25 · 2022: 16 · 2021: 27 · 2020: 45 · 2019: 51 · 2018: 40 · 2017: 2
- FWCI
- 33.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- American Journal of Nephrology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, type 2 diabetes, diabetic nephropathy, albuminuria, end-stage renal disease, cardiovascular outcomes, renal outcomes, CREDENCE trial, trial design, baseline characteristics
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.